Oncology-focused medical technology company TriSalus Life Sciences Inc. (TLSI) is gaining momentum as it expands its Pressure-Enabled Drug Delivery (PEDD) platform and TriNav product suite across solid tumor indications. With Phase I PERIO studies now complete and final data readouts expected in Q4 2025, the company is positioned at the intersection of commercial adoption and clinical innovation, making TLSI a compelling stock to watch in oncology-focused medical technology.
Launch of TriNav XP
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.